Pancreatic Cancer Research

ResearcherMario Negri Institute for Pharmacological ResearchNo recent work listed

Michela Cinquini

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-4452-9478; OpenAlex author ID A5025190469. Sources: OpenAlex.

Their work

Papers
2 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
12
Papers, trials and grants by year

2014: 1 paper · 2015: 1 paper

Papers 2

  1. The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib. Co-author DOI 10.18632/oncotarget.5197↗
  2. Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study. Last author DOI 10.1016/j.dld.2013.09.020↗

Closest collaborators

The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Roberto Labianca · 2 shared papers, 2014–2015 · strength 0.07
  2. Stefania Mosconi · 2 shared papers, 2014–2015 · strength 0.07
  3. Sandro Barni · 2 shared papers, 2014–2015 · strength 0.07
  4. Rossana Berardi · 2 shared papers, 2014–2015 · strength 0.07
  5. Luca Faloppi · 2 shared papers, 2014–2015 · strength 0.07
  6. Stefano Cascinu · 2 shared papers, 2014–2015 · strength 0.07
  7. Mario Scartozzi · 1 shared paper, 2015 · strength 0.04
  8. Kalliopi Andrikou · 1 shared paper, 2015 · strength 0.04
  9. Alessandro Bittoni · 1 shared paper, 2015 · strength 0.04
  10. Alberto Zaniboni · 1 shared paper, 2015 · strength 0.04
  11. Francesco Di Costanzo · 1 shared paper, 2014 · strength 0.03
  12. Giuseppe Tonini · 1 shared paper, 2014 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.